### RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis

Robert Bissonnette1, Joshua Rulloda2, Nadine Lee2, Paul Kassner2, Jasmina Jankicevic2, William Ho2, Laurence Cheng2, Emma Guttmann-Yassky3

1Innovaderm Research Inc., Montreal, Quebec, Canada, 2RAPT Therapeutics, Inc., South San Francisco, CA, USA, 3Icahn School of Medicine at Mount Sinai, New York, NY, USA

**BACKGROUND**

**RPT193 Targets Th2 Activity Responsible for Allergic Inflammation in Atopic Dermatitis, Asthma, and Other Diseases**

**Epithelial Barrier Dysfunction**

**Th2**

**CCL17 (TARC)**

**CCL22 (MDC)**

**CCR4**

**RPT193 is a potent and selective oral CCR4 antagonist that specifically inhibits Th2 cell migration, function, and activation.**

**KEY DATA PREVIOUSLY PRESENTED**

**Clinical Efficacy**

<table>
<thead>
<tr>
<th>Proportion of Patients</th>
<th>Placebo</th>
<th>RPT193</th>
</tr>
</thead>
<tbody>
<tr>
<td>EASI-50 Day 29</td>
<td>10.0%</td>
<td>40.2%</td>
</tr>
<tr>
<td>Day 43</td>
<td>20.0%</td>
<td>61.9%</td>
</tr>
<tr>
<td>EASI-75 Day 29</td>
<td>10.0%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Day 43</td>
<td>0.0%</td>
<td>28.6%</td>
</tr>
<tr>
<td>EASI-90 Day 29</td>
<td>0.0%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Day 43</td>
<td>0.0%</td>
<td>9.5%</td>
</tr>
<tr>
<td>vIGA Day 29</td>
<td>0.0%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Day 43</td>
<td>0.0%</td>
<td>14.3%</td>
</tr>
</tbody>
</table>

**RPT193 SIGNIFICANTLY DECREASES THE TOTAL SCORAD AND SUB-DOMAINS WITH CONTINUED IMPROVEMENT AFTER CESSATION OF TREATMENT**

**SCORAD Background**

- Developed in 1993
- Scored range from 0-103 with objective, investigator-assessed and subjective, patient-reported elements
- Objective
  - Six criteria signs are used to assess intensity or lesion severity
  - Extent of BSA affected by AD
- Subjective
  - Sleep loss and pruritus assessed individually
- Patients rate average for sleep loss and pruritus over the past 3 days using a visual analog scale

**Total SCORAD**

<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 8</th>
<th>Day 15</th>
<th>Day 29</th>
<th>Day 43</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

**RPT193 SIGNIFICANTLY DECREASES TWO KEY SYMPTOMS OF AD**

**SCORAD Pruritus and Sleep Loss**

<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 8</th>
<th>Day 15</th>
<th>Day 29</th>
<th>Day 43</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

**METHODS**

**Phase 1b Schematic**

**Key Trial Design Elements**

- Phase 1b trial part of a broader study conducted in healthy volunteers (HV) to investigate single and multiple doses of RPT193
- 400 mg dose selected based on safety, tolerability, PK and PD data from HV
- Double-blind, randomized, monotherapy study
- Primary and secondary endpoints were safety and PK, respectively
- Trial was not powered for any specific endpoint
- This poster focuses on SCORAD data
- Modified Intent to Treat (mITT) dataset with arithmetic means and standard error for continuous endpoints presented

**Baseline Patient Demographics and Characteristics**

**References**

5. EFTA, Dermatology (1993)